UNSPSC 51142520: Budipine

This classification denotes a cation channel blocker and antiparkinsonian agent with the molecular formula C21H27N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L9026OPI2Z, chemically known as 1-tert-butyl-4,4-diphenylpiperidine but generally known as budipine, which bears US NIH Compound Identifier 68778. Budipine most often comes in base and hydrochloride forms. European Medicines Agency schedules Budipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05956MIG.

UNSPSC 51142520 Budipine is a Commodity code under which state and local governments procure pharmaceutical products, specifically naloxone, drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products for community health, emergency response, and health benefit programs. Recent solicitations show that issuing bodies range from county health departments to state health and human services commissions to regional cooperative purchasing alliances, reflecting a mix of direct procurement and collaborative purchasing vehicles designed to serve multiple jurisdictions simultaneously.

Activity in this code spans Florida, Texas, and Minnesota with recent representation across the South and Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at establishing direct state pharmacy benefit relationships outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with a response deadline of March 26, 2026, and an effective date of July 1, 2026; this cooperative vehicle extends to participating jurisdictions including Oregon. Vendors responding to state and local opportunities under this code must meet FDA compliance, Drug Supply Chain Security Act certification, current Good Manufacturing Practices requirements, and maintain specified insurance coverage including commercial general liability and professional liability.